AVR

Anteris Technologies Glb

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

Australia

Next Earnings Date

05/12/26

Business Summary

Anteris Technologies Glb operates in Medical Devices, a capital-intensive, regulatory-driven industry where value is created through proprietary technology, clinical validation, and eventual commercialization or acquisition. The company’s model likely revolves around developing specialized cardiovascular or structural heart solutions and monetizing them through device sales or strategic partnerships. In this space, moat strength comes from intellectual property, clinical data, regulatory approvals, and surgeon adoption curves rather than brand alone. Cash generation ultimately depends on successfully moving from R&D burn to scaled device sales, but current financial metrics indicate it has not yet crossed that commercialization threshold.

VALUATION

P/E

-

Market Cap ($M USD)

$552

Forward P/E

-

PEG

-

PRICE TO SALES

109.9

PRICE TO BOOK

-

EV / EBITDA

-5.9

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$2.55

Next Year EPS Growth Estimate

-$0.97

Next Year Revenue Growth Estimate

58.30%

Return on Equity (ROE)

-

Operating Margin

-4920.90%

Debt-to-Equity

-

Piotroski F-Score

3

Altman Z-Score

-22

Return on Invested Capital (ROIC)

-285.70%%

Current Ratio

0.7

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is a $552M Healthcare name trading with no P/E, no Forward P/E, and no PEG Forward, which immediately signals the absence of earnings visibility and renders traditional GARP valuation frameworks unusable. A Price/Sales of 109.9 against EPS of -5.9 and ROIC of -285.70% is an extreme disconnect between market cap and operating reality. The Altman Z-Score of -22 combined with a Current Ratio of 0.7 screams financial distress risk, not growth durability. This is not a mispriced compounder; it is a highly speculative balance-sheet story where survival, not multiple expansion, is the primary question.

AI Exposure / Tech Reliance

As a Medical Devices company, it operates in a sector that can benefit from AI-driven diagnostics, imaging analytics, and procedural optimization, but there is nothing in the provided metrics that proves it is monetizing those shifts. With no earnings and deeply negative ROIC of -285.70%, technological leverage has not yet translated into economic returns. The industry tailwind exists, but the financials show no evidence of scalable AI-enabled operating leverage today.

The Bull Case

A speculative bull would argue that a $552M Market Cap in a high-value Medical Devices segment leaves room for asymmetric upside if commercialization inflects. The Piotroski F-Score of 3 is weak but not zero, suggesting there are at least a few foundational financial signals still intact. Consensus Rating of 3.60% and a Mean Consensus Target Price of 1.33 imply there is still some analyst sponsorship, and EPS improving from -5.9 to an estimated -$2.55 next year indicates losses are projected to narrow materially. If execution stabilizes and operating leverage emerges, even modest revenue scaling against a fixed cost base could dramatically re-rate a company trading purely on future optionality.

The Bear Case

The bear case is overwhelming. Debt/Equity of -4920.90% signals a severely impaired capital structure, and an Altman Z-Score of -22 places the company deep in financial distress territory. ROIC at -285.70% means capital is being destroyed at an extraordinary rate, while a Current Ratio of 0.7 indicates liquidity stress. A Price/Sales of 109.9 with negative EPS of -5.9 and no Forward P/E or PEG Forward suggests investors are paying a triple-digit revenue multiple for a business with no proven earnings power, which is structurally dangerous in a tightening capital environment.

Market Sentiment & Smart Money

Short Interest %

3.60%

Analyst Consensus

1.33

Average Analyst Price Target

$15.60

Institutional Ownership %

33.20%

1-Year Beta

2.07

Insider Buying % (6 Mo)

16.50%%

Distance to 52-Week High

81.70%%

Distance to 52-Week Low

242.70%%